Carly Whyte is an early-career researcher with expertise in the cellular and molecular mechanisms underlying immune-mediated pathology. Her research focuses on understanding how our immune systems can recognise and respond to cancer, with a view towards developing new immunotherapies for patients with solid tumours. She is supported by a Passe and Williams Junior Fellowship.
Dr Whyte holds a PhD in Immunology from the University of Adelaide, during which she discovered a previously unknown regulator of immune cell migration into tumours called ACKR4. She was then appointed as a postdoctoral research scientist at the Babraham Institute, Cambridge, UK and a Research Associate at Fitzwilliam College, University of Cambridge. During this... Read more
About me
Carly Whyte is an early-career researcher with expertise in the cellular and molecular mechanisms underlying immune-mediated pathology. Her research focuses on understanding how our immune systems can recognise and respond to cancer, with a view towards developing new immunotherapies for patients with solid tumours. She is supported by a Passe and Williams Junior Fellowship.
Dr Whyte holds a PhD in Immunology from the University of Adelaide, during which she discovered a previously unknown regulator of immune cell migration into tumours called ACKR4. She was then appointed as a postdoctoral research scientist at the Babraham Institute, Cambridge, UK and a Research Associate at Fitzwilliam College, University of Cambridge. During this postdoctoral training with Prof. Adrian Liston, Dr Whyte elucidated signaling networks of the cytokine IL-2, discovering novel mechanisms of action for this protein and identifying new regulatory networks which explained some of the common side-effects of therapeutic use of IL-2.
About me
Doctor of Philosophy University of Adelaide
Bachelor of Science (Honours) University of Adelaide
Bachelor of Science (Biomedical Science) University of Adelaide
Research
Excludes commercial-in-confidence projects.
Overcoming immune exhaustion in recurrent head and neck cancer, Garnett Passe & Rodney Williams Memorial Foundation-Conjoint Grant, 01/01/2025 - 31/12/2027
Defining the therapeutic potential of eosinophils in melanoma, Australian Melanoma Research Foundation, 01/02/2025 - 31/01/2026
Research
Research outputs for the last seven years are shown below. Some long-standing staff members may have older outputs included. To see earlier years visit ORCID or Scopus
Open access indicates that an output is open access.
| Year | Output |
|---|---|
| 2023 |
Open access
14
15
79
|
| 2022 |
Open access
26
25
72
|
| 2022 |
Open access
24
20
194
|
| 2022 |
Open access
112
110
278
|
| 2021 |
Open access
28
26
23
|
| 2021 |
Open access
25
23
28
|
| 2020 |
Open access
36
37
193
|
| 2020 |
Open access
230
219
287
|
| 2020 |
Open access
29
28
16
|
| 2019 |
81
81
23
|
| 2018 |
Open access
20
20
13
|
| 2017 |
Open access
26
26
1
|
| 2017 |
Open access
95
91
14
|
| 2015 |
Open access
112
107
92
|
External engagement & recognition
| Organisation | Country |
|---|---|
| Australian National University | AUSTRALIA |
| Babraham Institute | UNITED KINGDOM |
| Benaroya Research Institute | UNITED STATES |
| Catholic University of Leuven | BELGIUM |
| FlowJo (United States) | UNITED STATES |
| Free University of Amsterdam | NETHERLANDS |
| Ku Leuven | BELGIUM |
| Monash University | AUSTRALIA |
| QIMR Berghofer Medical Research Institute | AUSTRALIA |
| University Hospital Regensburg | GERMANY |
| University of Adelaide | AUSTRALIA |
| University of Cambridge | UNITED KINGDOM |
| University of Melbourne | AUSTRALIA |
| University of Queensland | AUSTRALIA |
| University of Rochester Medical Center | UNITED STATES |
| University of South Australia | AUSTRALIA |
| University of Washington | UNITED STATES |
| VIB Bioinformatics Core | BELGIUM |
| VIB-KU Leuven Center for Brain & Disease Research | BELGIUM |
| Walter and Eliza Hall Institute of Medical Research | AUSTRALIA |
| Wellcome Sanger Institute | UNITED KINGDOM |
